The first published randomised controlled trial of laser treatment for vaginal atrophy raises serious questions

• 1 The Wesley Hospital, Brisbane, QLD
• 2 University of Queensland, Brisbane, QLD

---

• 1. American College of Obstetricians and Gynecologists: Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration clearance: position statement. Washington, DC: ACOG, approved May 2016, reaffirmed July 2018. https://www.acog.org/Clinical-Guidance-and-Publications/Position-Statements/Fractional-Laser-Treatment-of-Vulvovaginal-Atrophy-and-US-Food-and-Drug-Administration-Clearance (viewed Sept 2018).
• 2. Therapeutic Goods Administration. Public summary for ARTG entry: 106780 High Tech Laser Australia P/L. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=B5C3E89B35339C9ECA2577DD0001F0EB&agid=(PrintDetailsPublic)&actionid=1 (viewed Feb 2018).
• 3. US Food and Drug Administration. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendations for clinical evaluation. Rockville, MD: FDA, 2003. https://www.fda.gov/downloads/Drugs/DrugSafety/informationbyDrugClass/UCM135338.pdf (viewed Feb 2018).
• 4. Chollet JA. Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence 2011; 5: 571-574.
• 5. Wurz GT, Kao CJ, DeGregorio MW. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging 2014; 9: 1939-1950.
• 6. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO₂ laser for vulvovaginal atrophy: a pilot study. Climacteric 2014; 17: 363-369.
• 7. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy. Climacteric 2015; 18: 219-225.
• 8. Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO₂ laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015; 22: 845-849.
• 9. Athanasiou S, Pitsouni E, Antonopoulou S, et al. The effect of microablative fractional CO₂ laser on vaginal flora of postmenopausal women. Climacteric 2016; 19: 512-518.
• 10. Pitsouni E, Grigoriadis T, Tsiveleka A, et al. Microablative fractional CO₂ laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas 2016; 94: 131-136.
• 11. Salvatore S, Pitsouni E, Del Deo F, et al. Sexual function in women suffering from genitourinary syndrome of menopause treated with fractionated CO₂ laser. Sex Med Rev 2017; 5: 486-494.
• 12. Athanasiou S, Pitsouni E, Falagas ME, et al. CO₂ laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas 2017; 104: 24-28.
• 13. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO₂ laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018; 25: 21-28.